TABLE 1.
Summary characteristics of the investigation cohort
| n | % | |
|---|---|---|
| Atorvastatin dosage | ||
| 5 mg q24h | 4 | 5.7 |
| 10 mg q24h | 14 | 20.0 |
| 20 mg q24h | 22 | 31.4 |
| 30 mg q24h | 1 | 1.4 |
| 40 mg q24h | 19 | 27.1 |
| 80 mg q24h | 10 | 14.3 |
| Indication | ||
| Primary prevention | 64 | 91.4 |
| Secondary prevention | 6 | 8.6 |
| Type of patient | ||
| De novo therapy | 19 | 27.1 |
| Recently switched statin | 12 | 17.1 |
| Long‐term treatment | 39 | 55.7 |
| Age (years) | ||
| Median (IQR) | 53.8 (21.6) | |
| Sex | ||
| Female | 35 | 50.0 |
| Male | 35 | 50.0 |
| BMI | ||
| median (IQR) | 26.0 (5.4) | |
| Smoker | ||
| No | 59 | 84.4 |
| 1–5 cigarettes/day | 3 | 4.3 |
| >5 cigarettes/day | 8 | 11.4 |
| Race | ||
| White | 66 | 94.3 |
| Hispanic | 2 | 2.9 |
| Other | 2 | 2.9 |
| Drug‐drug interactions | ||
| CYP3A inhibitors | 2 | 2.9 |
| CYP3A inducers | 0 | 0 |
| ABCB1 inhibitors | 1 | 1.4 |
| OATP1B1 inhibitors | 20 | 28.6 |
| OATP1B3 inhibitors | 0 | 0 |
| OATP2B1 inhibitors | 7 | 10.0 |
| Myalgia at any time during follow‐up | 6 | 8.6 |
Data given at baseline, unless noted otherwise.
Abbreviations: BMI, body mass index; IQR, interquartile range.